Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond
作者： Veaceslav Boldescu , Mira A. M. Behnam , Nikos Vasilakis , Christian D. Klein
DOI: 10.1038/NRD.2017.33
关键词:
摘要: Infections with flaviviruses, such as dengue, West Nile virus and the recently re-emerging Zika virus, are an increasing probably lasting global risk. This Review summarizes comments on opportunities for broad-spectrum agents that active against multiple flaviviruses. Broad-spectrum activity is particularly desirable to prepare next flaviviral epidemic, which could emerge from as-yet unknown or neglected viruses. Potential molecular targets antiflaviviral compounds include viral proteins, protease polymerase, host exploited by these viruses during entry replication, including α-glucosidase proteins involved in nucleoside biosynthesis. Numerous antiviral have already been identified target-specific phenotypic assays. For other compounds, can be anticipated because of their mode action targets.
nature.com
utsystem.edu参考文章(330)
Jean F. Borel, Götz Baumann, Ian Chapman, Peter Donatsch, Alfred Fahr, Edgar A. Mueller, Jean-Marie Vigouret, In Vivo Pharmacological Effects of Ciclosporin and Some Analogues Advances in pharmacology (San Diego). ,vol. 35, pp. 115- 246 ,(1996) , 10.1016/S1054-3589(08)60276-8
David Durantel, Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Current opinion in investigational drugs. ,vol. 10, pp. 860- ,(2009)
Akira HABU, Yosuke MURAKAMI, Akira OGASA, Yujiro FUJISAKI, [Disorder of spermatogenesis and viral discharge into semen in boars infected with Japanese encephalitis virus (author's transl)]. Uirusu. ,vol. 27, pp. 21- 26 ,(1977) , 10.2222/JSV.27.21
William G. Powderly, Margaret A. Fischl, Lionel Resnick, Kenneth H. Fife, Robert J. Fass, Susan L. Smith, Alton B. Kremer, Carl Bertil Wallemark, Kenneth G. Kowalski, John C. Pottage, Robert Coombs, Richard L. Aspinall, Ann C. Collier, The safety and efficacy of combination N-butyl-deoxynojirimycin (SC- 48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3 Journal of Acquired Immune Deficiency Syndromes. ,vol. 7, pp. 139- 147 ,(1994)
Michael J. Sofia, Nucleotide Prodrugs for the Treatment of HCV Infection Advances in pharmacology. ,vol. 67, pp. 39- 73 ,(2013) , 10.1016/B978-0-12-405880-4.00002-0
Allan Bastos Lima, Mira A.M. Behnam, Yasmin El Sherif, Christoph Nitsche, Sergio M. Vechi, Christian D. Klein, Dual inhibitors of the dengue and West Nile virus NS2B-NS3 proteases: Synthesis, biological evaluation and docking studies of novel peptide-hybrids. Bioorganic & Medicinal Chemistry. ,vol. 23, pp. 5748- 5755 ,(2015) , 10.1016/J.BMC.2015.07.012
Turgut E. Aktepe, Helen Pham, Jason M. Mackenzie, Differential utilisation of ceramide during replication of the flaviviruses West Nile and dengue virus. Virology. ,vol. 484, pp. 241- 250 ,(2015) , 10.1016/J.VIROL.2015.06.015
Jacob Nelson, Kelsey Roe, Beverly Orillo, Pei-Yong Shi, Saguna Verma, None, Combined treatment of adenosine nucleoside inhibitor NITD008 and histone deacetylase inhibitor vorinostat represents an immunotherapy strategy to ameliorate West Nile virus infection. Antiviral Research. ,vol. 122, pp. 39- 45 ,(2015) , 10.1016/J.ANTIVIRAL.2015.07.008
Sri Rezeki Hadinegoro, Jose Luis Arredondo-García, Maria Rosario Capeding, Carmen Deseda, Tawee Chotpitayasunondh, Reynaldo Dietze, HI Hj Muhammad Ismail, Humberto Reynales, Kriengsak Limkittikul, Doris Maribel Rivera-Medina, Huu Ngoc Tran, Alain Bouckenooghe, Danaya Chansinghakul, Margarita Cortés, Karen Fanouillere, Remi Forrat, Carina Frago, Sophia Gailhardou, Nicholas Jackson, Fernando Noriega, Eric Plennevaux, T Anh Wartel, Betzana Zambrano, Melanie Saville, None, Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease The New England Journal of Medicine. ,vol. 373, pp. 1195- 1206 ,(2015) , 10.1056/NEJMOA1506223
Yen-Liang Chen, Fumiaki Yokokawa, Pei-Yong Shi, The search for nucleoside/nucleotide analog inhibitors of dengue virus. Antiviral Research. ,vol. 122, pp. 12- 19 ,(2015) , 10.1016/J.ANTIVIRAL.2015.07.010